Moderna’s stock was surging after the FDA said it would review the biotech’s flu-vaccine candidate, a week after it had refused to do so.
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Related Posts
Popular News
Latest News
Palo Alto Networks’ stock falls after earnings. These analysts see a good chance to buy.
Some analysts encourage investors to look past a muddy outlook and focus on the company’s recent momentum and AI opportunity.
Bitcoin Charts Project Fresh Lows In $50K Range: Will Altcoins Follow?
Key points:Bitcoin remains under pressure, and the downside might accelerate if the $65,118 level is breached.Several major altcoins are attempting...
Fed minutes reveal discussion of a possible rate hike if inflation doesn’t cool
Several officials would have supported a statement by the Fed indicating rates could rise if inflation remained high.
10 things I’ve learned about running a business from home
In 2014 I set up Word Dragon (it was called CV Shed in those days). It was never part of...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.